Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in…
5 analysts rate AKBA Buy on consensus.
Consensus price target: $4.40 (+932.86% upside from $0.43)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Ostrowski Erik SVP, CFO, CBO & Treasurer | Jun 29, 2026 | Sale | 56,019 | $62.18K |
| Butler John P. director, CEO and President | Mar 4, 2026 | Purchase | 69,270 | $86.59K |
| Butler John P. director, CEO and President | Feb 2, 2026 | Sale | 114,891 | $159.7K |
| Butler John P. director, CEO and President | Feb 2, 2026 | Sale | 83,689 | $116.33K |
| Butler John P. director, CEO and President | Feb 2, 2026 | Sale | 96,065 | $133.53K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $236.2M | +47.46% | $-5.35M |
| 2024 | $160.18M | -17.7% | $-69.41M |
| 2023 | $194.62M | -33.46% | $-51.93M |
Stock data for AKBA: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics